Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism

When administered chronically to rats, drugs that are effective in bipolar disorder-lithium and the anticonvulsants, valproic acid and carbamazepine-have been shown to downregulate the expression of certain enzymes involved in brain arachidonic acid (AA) release and cyclooxygenase (COX)-mediated met...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychopharmacologia 2005-07, Vol.180 (3), p.523-529
Hauptverfasser: GHELARDONI, Sandra, BAZINET, Richard P, RAPOPORT, Stanley I, BOSETTI, Francesca
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 529
container_issue 3
container_start_page 523
container_title Psychopharmacologia
container_volume 180
creator GHELARDONI, Sandra
BAZINET, Richard P
RAPOPORT, Stanley I
BOSETTI, Francesca
description When administered chronically to rats, drugs that are effective in bipolar disorder-lithium and the anticonvulsants, valproic acid and carbamazepine-have been shown to downregulate the expression of certain enzymes involved in brain arachidonic acid (AA) release and cyclooxygenase (COX)-mediated metabolism. Phase II clinical trials with the anticonvulsant topiramate [2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate] suggest that this drug may also be effective for bipolar disorder. To see if topiramate has effects similar to those of the other three drugs, we administered topiramate to rats for 14 days at 20 mg/kg, p.o. twice daily. Compared with p.o. vehicle, topiramate treatment did not significantly affect the brain activity or protein level of cytosolic phospholipase A2, secretory PLA2, or Ca2+-independent iPLA2. Additionally, brain protein levels of COX-1, COX-2, 5-lipoxygenase, and cytochrome P450 epoxygenase were unchanged. These results suggest that topiramate does not modify expression of the enzymes involved in brain AA metabolism that have been shown to be targeted by lithium, valproic acid, or carbamazepine. If topiramate proves effective in bipolar disorder, it may not act by modulating brain AA metabolism. In view of the proven anticonvulsant effect of topiramate, our results also suggest that the AA cascade is not involved in the anti-seizure properties of the drug.
doi_str_mv 10.1007/s00213-005-2189-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67940530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17098332</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-487ff04df0e1e923c085c6c59b545a785c81dff993029039907af8f4050f34223</originalsourceid><addsrcrecordid>eNqFkU-LFDEQxYMo7rj6AbxIEPTWWkklk-Qoi_9gwct68hBq0glm6e6MSQ-4--nNOAMLXswlL_B7j6o8xl4KeCcAzPsGIAUOAHqQwroBH7GNUCgHCUY-ZhsAxAGFthfsWWu30I-y6im7ENoI1y0b9uOm7HOlmdbIxxIbX8rKaVpj5fH3vsbWcll4Xnille8qdVUSj8v93dzhLqlS-JnHsuTAKeSRz3GlXZlym5-zJ4mmFl-c70v2_dPHm6svw_W3z1-vPlwPAa1ZB2VNSqDGBFFEJzGA1WEbtNtppcn0hxVjSs4hSAfoHBhKNinQkFBJiZfs7Sl3X8uvQ2yrn3MLcZpoieXQ_Na4DiP8FxQGnEU8Jr7-B7wth7r0Jfzxo5VyqDskTlCopbUak9_XPFO98wL8sR9_6sf3fv7aPHbPq3PwYTfH8cFxLqQDb84AtUBTqrSE3B64rTVb02f8Aw4ylqA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218944935</pqid></control><display><type>article</type><title>Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>GHELARDONI, Sandra ; BAZINET, Richard P ; RAPOPORT, Stanley I ; BOSETTI, Francesca</creator><creatorcontrib>GHELARDONI, Sandra ; BAZINET, Richard P ; RAPOPORT, Stanley I ; BOSETTI, Francesca</creatorcontrib><description>When administered chronically to rats, drugs that are effective in bipolar disorder-lithium and the anticonvulsants, valproic acid and carbamazepine-have been shown to downregulate the expression of certain enzymes involved in brain arachidonic acid (AA) release and cyclooxygenase (COX)-mediated metabolism. Phase II clinical trials with the anticonvulsant topiramate [2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate] suggest that this drug may also be effective for bipolar disorder. To see if topiramate has effects similar to those of the other three drugs, we administered topiramate to rats for 14 days at 20 mg/kg, p.o. twice daily. Compared with p.o. vehicle, topiramate treatment did not significantly affect the brain activity or protein level of cytosolic phospholipase A2, secretory PLA2, or Ca2+-independent iPLA2. Additionally, brain protein levels of COX-1, COX-2, 5-lipoxygenase, and cytochrome P450 epoxygenase were unchanged. These results suggest that topiramate does not modify expression of the enzymes involved in brain AA metabolism that have been shown to be targeted by lithium, valproic acid, or carbamazepine. If topiramate proves effective in bipolar disorder, it may not act by modulating brain AA metabolism. In view of the proven anticonvulsant effect of topiramate, our results also suggest that the AA cascade is not involved in the anti-seizure properties of the drug.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-005-2189-3</identifier><identifier>PMID: 15719218</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Administration, Oral ; Animals ; Anticonvulsants. Antiepileptics. Antiparkinson agents ; Arachidonic Acid - metabolism ; Biological and medical sciences ; Blotting, Western ; Body Weight - drug effects ; Brain - drug effects ; Brain - enzymology ; Fructose - administration &amp; dosage ; Fructose - analogs &amp; derivatives ; Fructose - pharmacology ; Immunoenzyme Techniques ; Leptin - blood ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Phospholipases A - metabolism ; Phospholipases A2 ; Prostaglandin-Endoperoxide Synthases - metabolism ; Rats ; Rats, Inbred F344 ; Time Factors</subject><ispartof>Psychopharmacologia, 2005-07, Vol.180 (3), p.523-529</ispartof><rights>2005 INIST-CNRS</rights><rights>Springer-Verlag 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-487ff04df0e1e923c085c6c59b545a785c81dff993029039907af8f4050f34223</citedby><cites>FETCH-LOGICAL-c387t-487ff04df0e1e923c085c6c59b545a785c81dff993029039907af8f4050f34223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16876783$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15719218$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GHELARDONI, Sandra</creatorcontrib><creatorcontrib>BAZINET, Richard P</creatorcontrib><creatorcontrib>RAPOPORT, Stanley I</creatorcontrib><creatorcontrib>BOSETTI, Francesca</creatorcontrib><title>Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology (Berl)</addtitle><description>When administered chronically to rats, drugs that are effective in bipolar disorder-lithium and the anticonvulsants, valproic acid and carbamazepine-have been shown to downregulate the expression of certain enzymes involved in brain arachidonic acid (AA) release and cyclooxygenase (COX)-mediated metabolism. Phase II clinical trials with the anticonvulsant topiramate [2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate] suggest that this drug may also be effective for bipolar disorder. To see if topiramate has effects similar to those of the other three drugs, we administered topiramate to rats for 14 days at 20 mg/kg, p.o. twice daily. Compared with p.o. vehicle, topiramate treatment did not significantly affect the brain activity or protein level of cytosolic phospholipase A2, secretory PLA2, or Ca2+-independent iPLA2. Additionally, brain protein levels of COX-1, COX-2, 5-lipoxygenase, and cytochrome P450 epoxygenase were unchanged. These results suggest that topiramate does not modify expression of the enzymes involved in brain AA metabolism that have been shown to be targeted by lithium, valproic acid, or carbamazepine. If topiramate proves effective in bipolar disorder, it may not act by modulating brain AA metabolism. In view of the proven anticonvulsant effect of topiramate, our results also suggest that the AA cascade is not involved in the anti-seizure properties of the drug.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents</subject><subject>Arachidonic Acid - metabolism</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Body Weight - drug effects</subject><subject>Brain - drug effects</subject><subject>Brain - enzymology</subject><subject>Fructose - administration &amp; dosage</subject><subject>Fructose - analogs &amp; derivatives</subject><subject>Fructose - pharmacology</subject><subject>Immunoenzyme Techniques</subject><subject>Leptin - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phospholipases A - metabolism</subject><subject>Phospholipases A2</subject><subject>Prostaglandin-Endoperoxide Synthases - metabolism</subject><subject>Rats</subject><subject>Rats, Inbred F344</subject><subject>Time Factors</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkU-LFDEQxYMo7rj6AbxIEPTWWkklk-Qoi_9gwct68hBq0glm6e6MSQ-4--nNOAMLXswlL_B7j6o8xl4KeCcAzPsGIAUOAHqQwroBH7GNUCgHCUY-ZhsAxAGFthfsWWu30I-y6im7ENoI1y0b9uOm7HOlmdbIxxIbX8rKaVpj5fH3vsbWcll4Xnille8qdVUSj8v93dzhLqlS-JnHsuTAKeSRz3GlXZlym5-zJ4mmFl-c70v2_dPHm6svw_W3z1-vPlwPAa1ZB2VNSqDGBFFEJzGA1WEbtNtppcn0hxVjSs4hSAfoHBhKNinQkFBJiZfs7Sl3X8uvQ2yrn3MLcZpoieXQ_Na4DiP8FxQGnEU8Jr7-B7wth7r0Jfzxo5VyqDskTlCopbUak9_XPFO98wL8sR9_6sf3fv7aPHbPq3PwYTfH8cFxLqQDb84AtUBTqrSE3B64rTVb02f8Aw4ylqA</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>GHELARDONI, Sandra</creator><creator>BAZINET, Richard P</creator><creator>RAPOPORT, Stanley I</creator><creator>BOSETTI, Francesca</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20050701</creationdate><title>Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism</title><author>GHELARDONI, Sandra ; BAZINET, Richard P ; RAPOPORT, Stanley I ; BOSETTI, Francesca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-487ff04df0e1e923c085c6c59b545a785c81dff993029039907af8f4050f34223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Anticonvulsants. Antiepileptics. Antiparkinson agents</topic><topic>Arachidonic Acid - metabolism</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Body Weight - drug effects</topic><topic>Brain - drug effects</topic><topic>Brain - enzymology</topic><topic>Fructose - administration &amp; dosage</topic><topic>Fructose - analogs &amp; derivatives</topic><topic>Fructose - pharmacology</topic><topic>Immunoenzyme Techniques</topic><topic>Leptin - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phospholipases A - metabolism</topic><topic>Phospholipases A2</topic><topic>Prostaglandin-Endoperoxide Synthases - metabolism</topic><topic>Rats</topic><topic>Rats, Inbred F344</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GHELARDONI, Sandra</creatorcontrib><creatorcontrib>BAZINET, Richard P</creatorcontrib><creatorcontrib>RAPOPORT, Stanley I</creatorcontrib><creatorcontrib>BOSETTI, Francesca</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GHELARDONI, Sandra</au><au>BAZINET, Richard P</au><au>RAPOPORT, Stanley I</au><au>BOSETTI, Francesca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism</atitle><jtitle>Psychopharmacologia</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>180</volume><issue>3</issue><spage>523</spage><epage>529</epage><pages>523-529</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>When administered chronically to rats, drugs that are effective in bipolar disorder-lithium and the anticonvulsants, valproic acid and carbamazepine-have been shown to downregulate the expression of certain enzymes involved in brain arachidonic acid (AA) release and cyclooxygenase (COX)-mediated metabolism. Phase II clinical trials with the anticonvulsant topiramate [2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate] suggest that this drug may also be effective for bipolar disorder. To see if topiramate has effects similar to those of the other three drugs, we administered topiramate to rats for 14 days at 20 mg/kg, p.o. twice daily. Compared with p.o. vehicle, topiramate treatment did not significantly affect the brain activity or protein level of cytosolic phospholipase A2, secretory PLA2, or Ca2+-independent iPLA2. Additionally, brain protein levels of COX-1, COX-2, 5-lipoxygenase, and cytochrome P450 epoxygenase were unchanged. These results suggest that topiramate does not modify expression of the enzymes involved in brain AA metabolism that have been shown to be targeted by lithium, valproic acid, or carbamazepine. If topiramate proves effective in bipolar disorder, it may not act by modulating brain AA metabolism. In view of the proven anticonvulsant effect of topiramate, our results also suggest that the AA cascade is not involved in the anti-seizure properties of the drug.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>15719218</pmid><doi>10.1007/s00213-005-2189-3</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacologia, 2005-07, Vol.180 (3), p.523-529
issn 0033-3158
1432-2072
language eng
recordid cdi_proquest_miscellaneous_67940530
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Administration, Oral
Animals
Anticonvulsants. Antiepileptics. Antiparkinson agents
Arachidonic Acid - metabolism
Biological and medical sciences
Blotting, Western
Body Weight - drug effects
Brain - drug effects
Brain - enzymology
Fructose - administration & dosage
Fructose - analogs & derivatives
Fructose - pharmacology
Immunoenzyme Techniques
Leptin - blood
Male
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Phospholipases A - metabolism
Phospholipases A2
Prostaglandin-Endoperoxide Synthases - metabolism
Rats
Rats, Inbred F344
Time Factors
title Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T18%3A39%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Topiramate%20does%20not%20alter%20expression%20in%20rat%20brain%20of%20enzymes%20of%20arachidonic%20acid%20metabolism&rft.jtitle=Psychopharmacologia&rft.au=GHELARDONI,%20Sandra&rft.date=2005-07-01&rft.volume=180&rft.issue=3&rft.spage=523&rft.epage=529&rft.pages=523-529&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/s00213-005-2189-3&rft_dat=%3Cproquest_cross%3E17098332%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218944935&rft_id=info:pmid/15719218&rfr_iscdi=true